ProCE Banner Activity

EMN30/MajesTEC-4: Safety Run-in Data From Phase III Trial of Teclistamab ± Lenalidomide Maintenance Therapy in Newly Diagnosed Multiple Myeloma After ASCT

Conference Coverage
Slideset

In initial safety results from EMN30/MajesTEC-4, fixed-duration teclistamab, with or without lenalidomide, was safe and tolerable as maintenance therapy in patients with newly diagnosed multiple myeloma following autologous stem cell transplantation.

Released: December 13, 2024

Expiration: December 12, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation